596 related articles for article (PubMed ID: 34522589)
1. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.
Han L; Jiang C
Acta Pharm Sin B; 2021 Aug; 11(8):2306-2325. PubMed ID: 34522589
[TBL] [Abstract][Full Text] [Related]
2. Escape from abluminal LRP1-mediated clearance for boosted nanoparticle brain delivery and brain metastasis treatment.
Khan NU; Ni J; Ju X; Miao T; Chen H; Han L
Acta Pharm Sin B; 2021 May; 11(5):1341-1354. PubMed ID: 34094838
[TBL] [Abstract][Full Text] [Related]
3. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
4. Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis.
Zhu D; Su Y; Fu B; Xu H
Mol Neurobiol; 2018 Sep; 55(9):7118-7131. PubMed ID: 29383689
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Mfsd2a-Mediated Low Transcytosis to Boost Nanoparticle Delivery to Brain for Chemotherapy of Brain Metastases.
Ju X; Miao T; Chen H; Ni J; Han L
Adv Healthc Mater; 2021 May; 10(9):e2001997. PubMed ID: 33738958
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated inhibition of tissue-type plasminogen activator binding to the low-density lipoprotein receptor-related protein 1 as a potential beneficial modulator for stroke therapy.
Klecker PH; Fritzen L; Mazura AD; Weggen S; Pietrzik CU
J Cell Biochem; 2023 Jul; 124(7):1040-1049. PubMed ID: 37288821
[TBL] [Abstract][Full Text] [Related]
7. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.
Storck SE; Hartz AMS; Bernard J; Wolf A; Kachlmeier A; Mahringer A; Weggen S; Pahnke J; Pietrzik CU
Brain Behav Immun; 2018 Oct; 73():21-33. PubMed ID: 30041013
[TBL] [Abstract][Full Text] [Related]
8. Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
Tashima T
Chem Pharm Bull (Tokyo); 2020; 68(4):316-325. PubMed ID: 32238649
[TBL] [Abstract][Full Text] [Related]
9. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
10. Human induced pluripotent stem cells (BIONi010-C) generate tight cell monolayers with blood-brain barrier traits and functional expression of large neutral amino acid transporter 1 (SLC7A5).
Goldeman C; Andersen M; Al-Robai A; Buchholtz T; Svane N; Ozgür B; Holst B; Shusta E; Hall VJ; Saaby L; Hyttel P; Brodin B
Eur J Pharm Sci; 2021 Jan; 156():105577. PubMed ID: 33011235
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury.
Khalin I; Alyautdin R; Wong TW; Gnanou J; Kocherga G; Kreuter J
Drug Deliv; 2016 Nov; 23(9):3520-3528. PubMed ID: 27278330
[TBL] [Abstract][Full Text] [Related]
12. Mfsd2a (Major Facilitator Superfamily Domain Containing 2a) Attenuates Intracerebral Hemorrhage-Induced Blood-Brain Barrier Disruption by Inhibiting Vesicular Transcytosis.
Yang YR; Xiong XY; Liu J; Wu LR; Zhong Q; Zhou K; Meng ZY; Liu L; Wang FX; Gong QW; Liao MF; Duan CM; Li J; Yang MH; Zhang Q; Gong CX; Yang QW
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724654
[TBL] [Abstract][Full Text] [Related]
13. Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier.
Wang JZ; Xiao N; Zhang YZ; Zhao CX; Guo XH; Lu LM
Pharmacol Res; 2016 Feb; 104():124-31. PubMed ID: 26747400
[TBL] [Abstract][Full Text] [Related]
14. Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins.
Wan W; Cao L; Liu L; Zhang C; Kalionis B; Tai X; Li Y; Xia S
J Neurochem; 2015 Jul; 134(2):382-93. PubMed ID: 25866188
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
16. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2.
Kou L; Hou Y; Yao Q; Guo W; Wang G; Wang M; Fu Q; He Z; Ganapathy V; Sun J
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1605-1616. PubMed ID: 28974108
[TBL] [Abstract][Full Text] [Related]
17. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease.
Wang P; Zheng X; Guo Q; Yang P; Pang X; Qian K; Lu W; Zhang Q; Jiang X
J Control Release; 2018 Jun; 279():220-233. PubMed ID: 29679667
[TBL] [Abstract][Full Text] [Related]
18. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage.
Sun K; Fan J; Han J
Acta Pharm Sin B; 2015 Jan; 5(1):8-24. PubMed ID: 26579420
[TBL] [Abstract][Full Text] [Related]
19. LRP1-upregulated nanoparticles for efficiently conquering the blood-brain barrier and targetedly suppressing multifocal and infiltrative brain metastases.
Guo Q; Zhu Q; Miao T; Tao J; Ju X; Sun Z; Li H; Xu G; Chen H; Han L
J Control Release; 2019 Jun; 303():117-129. PubMed ID: 31026546
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in nanomedicines for the treatment of ischemic stroke.
Li C; Sun T; Jiang C
Acta Pharm Sin B; 2021 Jul; 11(7):1767-1788. PubMed ID: 34386320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
